Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024.

Autor:	Cosman F; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, United States., Lewiecki EM; New Mexico Clinical Research & Osteoporosis Center, Division of Metabolic Bone Diseases, Albuquerque, NM 87106, United States., Eastell R; Division of Clinical Medicine, University of Sheffield, Sheffield S10 2RX, United Kingdom., Ebeling PR; Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia., Jan De Beur S; Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, VA 22908, United States., Langdahl B; Department of Endocrinology, Aarhus University Hospital, Aarhus N 8200, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus N 8200, Denmark., Rhee Y; Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul 03722, South Korea., Fuleihan GE; Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut, Beirut 1107, Lebanon., Kiel DP; Marcus Institute for Aging Research, Hebrew Senior Life, Boston, MA 02131, United States.; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States., Schousboe JT; Division of Research and Evaluation, HealthPartners Institute, Bloomington MN 55425, United States.; Division of Health Policy and Management, University of Minnesota, Minneapolis, MN 55425, United States., Borges JL; Brazil Clinical Research Center, Brasilia 71625-175, Brazil., Cheung AM; Department of Medicine and Joint Department of Medical Imaging, University Health Network, Toronto, ON M5G 2C4, Canada.; Centre of Excellence in Skeletal Health Assessment, University of Toronto, Toronto, ON M5G 2C4, Canada., Diez-Perez A; Department of Medicine, Institute Hospital del Mar of Medical Investigation, Barcelona 08003, Spain., Hadji P; Department of Obstetrics and Gynecology, Frankfurt Center of Bone Health and Phillipps-University of Marburg, Frankfurt 60313, Germany., Tanaka S; Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan., Thomasius F; Department of Clinical Osteology, Frankfurt Center of Bone Health and Endocrinology, Frankfurt 60313, Germany., Xia W; Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China., Cummings SR; San Francisco Coordinating Center, CPMC Research Institute, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158, United States.
Jazyk:	angličtina
Zdroj:	Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2024 Sep 26; Vol. 39 (10), pp. 1393-1405.
DOI:	10.1093/jbmr/zjae119
Abstrakt:	The overarching goal of osteoporosis management is to prevent fractures. A goal-directed approach to long-term management of fracture risk helps ensure that the most appropriate initial treatment and treatment sequence is selected for individual patients. Goal-directed treatment decisions require assessment of clinical fracture history, vertebral fracture identification (using vertebral imaging as appropriate), measurement of bone mineral density (BMD), and consideration of other major clinical risk factors. Treatment targets should be tailored to each patient's individual risk profile and based on the specific indication for beginning treatment, including recency, site, number and severity of prior fractures, and BMD levels at the total hip, femoral neck, and lumbar spine. Instead of first-line bisphosphonate treatment for all patients, selection of initial treatment should focus on reducing fracture risk rapidly for patients at very high and imminent risk, such as in those with recent fractures. Initial treatment selection should also consider the probability that a BMD treatment target can be attained within a reasonable period of time and the differential magnitude of fracture risk reduction and BMD impact with osteoanabolic versus antiresorptive therapy. This position statement of the ASBMR/BHOF Task Force on Goal-Directed Osteoporosis Treatment provides an overall summary of the major clinical recommendations about treatment targets and strategies to achieve those targets based on the best evidence available, derived primarily from studies in older postmenopausal women of European ancestry. (© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu